Former Sequenom R&D Chief Charged by SEC | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Securities and Exchange Commission today said that it has charged a former executive of Sequenom with making false statements to investors about the firm's prenatal test for Down syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.